Articles from Candid Therapeutics, Inc.

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation studies in oncology patients.

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBodyTM. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026.

Candid Therapeutics, Inc. (“Candid”), a clinical stage biotechnology company positioned to lead the development of T cell engagers for autoimmune diseases and Ab Studio, Inc. (“Ab Studio”), a US biotech focused on the discovery of novel antibodies via computer-aided design, announced that the companies have entered a strategic research collaboration to discover and develop novel T Cell Engager program candidates for various autoimmune indications.

Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune diseases, and EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical-stage biopharmaceutical company specializing in the discovery and development of multi-specific antibodies for diseases with high unmet need, announced that the companies have entered a strategic research collaboration to discover and develop novel T-cell Engager program candidates for various autoimmune indications.

Candid Therapeutics, Inc. (“Candid”), a clinical stage biotechnology company positioned to lead the development of T-cell engagers for autoimmune diseases, appointed repeatedly successful industry veterans, Angie You, Ph.D. and Dan Puckett, to its board of directors.

Candid Therapeutics, Inc. (“Candid”), a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, announced its official launch today.